Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies [mouse]

ABSTRACT: A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies [mouse]

PROVIDER: PRJNA1162886 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR30730288.fastq.gz	Fastqsanger.gz
	SRR30730289.fastq.gz	Fastqsanger.gz
	SRR30730290.fastq.gz	Fastqsanger.gz
	SRR30730291.fastq.gz	Fastqsanger.gz
	SRR30730292.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies

Project description:A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies

| PRJNA1160801 | ENA

A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies.

Project description:A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies.

| PRJNA1094882 | ENA

A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies

Project description:A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies

| PRJNA1162874 | ENA

A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies

Project description:Myeloid cancers such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) remain resistant to standard of care (SOC) and targeted therapies. Here, we identify an oncogenic signal from the niche as a mechanism determining response to all trans-retinoic acid (ATRA), a regimen with disparate results in AML. In samples from clinical trials, responsiveness to ATRA correlates with activation of b-catenin/JAG1 in osteoblastic lineage cells and Notch1 signaling in MDS/AML cells of patients. ATRA inhibits b-catenin activation in patients and leukemic mice. As a result, it specifically suppresses growth and survival and promotes differentiation of MDS/AML cells solely from patients with active b-catenin/JAG1 signaling. This event is independent of cytogenetics and mutational profile. ATRA also improves disease outcome in mice with no evidence of relapse and a superior safety profile to SOC. A circulating skeletal stem cell population expressing activated b-catenin allows patient stratification and monitoring treatment response. A human blocking antibody against JAG1 further improves efficacy, curing mice from leukemia and maintaining the beneficial effects on patient-derived MDS/AML cells. These results demonstrate a niche-directed therapeutic approach, tailored to at least 1/3 of MDS/AML patients that can evade relapse and overcome SOC toxicity, highlighting the therapeutic potential of targeting the niche. b-catenin activation provides an explanation for the differential response to ATRA and a mechanistic biomarker for immediate ATRA repurposing in myeloid malignancies, potentially extending in a broad range of cancers.

2025-01-28 | GSE277588 | GEO

A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies

2025-01-28 | GSE277103 | GEO

A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies [mouse]

2025-01-28 | GSE277597 | GEO

A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies.

Project description:Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) remain resistant to standard of care (SOC) and targeted therapies. Here, we identify an oncogenic signal from the niche as a mechanism determining response to all-trans-retinoic acid (ATRA), a regiment with disparate results in AML. In reported clinical trials responsiveness to ATRA correlates with activation of b-catenin/JAG1 in osteoblasts and Notch1 signaling in MDS/AML cells. ATRA inhibits osteoblastic b-catenin activation in patients and leukemic mice and thus suppresses patient MDS/AML cell growth and survival and promotes their differentiation independent of cytogenetics and mutational profile. ATRA also improves disease outcome in mice with no evidence of relapse and a superior safety profile as compared to SOC. A circulating skeletal stem cell population expressing activated b-catenin allows patient stratification and monitoring treatment response. A human blocking antibody against JAG1 further improves efficacy, curing mice from leukemia and maintaining the beneficial effects on patient-derived MDS/AML cells. These findings provide a mechanistic biomarker for immediate ATRA repurposing in MDS/AML and demonstrate the therapeutic potential of targeting the niche to evade relapse and overcome toxicity.

2025-01-28 | GSE262907 | GEO

Uropathogenic E. coli Niche-Occupancy Determines the Effects of Mucosal Vaccine Against FimH

Project description:Uropathogenic E. coli Niche-Occupancy Determines the Effects of Mucosal Vaccine Against FimH

| PRJEB81667 | ENA

A Novel Osteoclastic Network Determines Niche for Mouse Hematopoietic Stem Cells In Vitro

Project description:The importance of extrinsic regulation of hematopoietic stem cell activity is increasingly acknowledged. Here we report the generation of a new niche system, which supports expansion of mouse hematopoietic stem cells in vitro. Characterization of this niche revealed a transcriptional regulatory network including four critical factors, namely FOS, SPI1, KLF10 and TFEC. Interestingly, these factors are essential for osteoclastogenesis, thus revealing an osteoclastic network that supports hematopoietic stem cell self-renewal. Lentiviral vectors containing putative transcription factors regulating HSC expansion were transfected into GPE cells and gene expression values were compared to empty vector controls.

2013-12-31 | E-GEOD-39835 | biostudies-arrayexpress

Salmonella mediated intracellular niche control by SCV size regulation

Project description:Salmonella is a human and animal pathogen causing gastro-enteric diseases worldwide. The key feature of Salmonella infection is its entry into intestinal epithelial cells within a Salmonella-Containing Vacuole (SCV). This original compartment is distinct from empty macropinosomes formed around the infection site. A few minutes after its formation, the SCV increases in size through fusions with the surrounding macropinosomes. On the opposite, Salmonella induces the formation of elongated tubules leading to SCV membrane and volume loss. Later, the SCV can mature into a vacuolar pathogen niche, or be ruptured releasing Salmonella in the host cytosol where the bacteria hyper-replicates. Here, we describe how size control of the early SCV is the main contributor to its stability and consequently determines the Salmonella intracellular niche and growth. We identify the SNAREs required for increasing the SCV size through fusions. We show that this fusion promotes the maintenance of the SCV integrity and the establishment of a vacuolar niche

2020-01-09 | PXD012825 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data